Immune response is now part of the essential and desirable diagnostic criteria for colorectal cancers in the 5th edition of The WHO Classification of Tumours

Update 17 August 2022 – Everything Genetic no longer provides this testing service.

The World Health Organization (WHO), in its latest edition of the Digestive System Tumours (5th edition), introduced immune response as an essential and desirable diagnostic criteria for colorectal cancer, in addition to traditional histological parameters.

Commercialised by HalioDx in more than 20 countries for patients with localised colon cancer, and distributed here in the UK by Everything Genetic, Immunoscore® is an in vitro diagnostic test quantifying the immune response for predicting cancer recurrence and personalising patterns of care[1]. The standardised method used in the SITC validation effort (i.e. Immunoscore®) is referenced in the WHO.

Classification of Tumours, 5th edition, as the most recent evidence of the immune response prognostic power in colon cancer (Pagès et al. Lancet 2018). Immune response assessment is now an essential complement to the traditional TNM[2] staging system in colon cancer, Immunoscore® being the reference assay for its evaluation.

Dr Jérôme Galon, the inventor of Immunoscore® says: “The introduction of the Immune response assessment for colon cancer patients in the WHO classification rewards 15 years of translational research efforts on Immunoscore® with a significant impact on standard of care. This effort is a collective success including numerous French and international collaborators. We are now investing significant efforts in demonstrating Immunoscore® clinical utility, beyond colon cancer, in a broad range of indications”.

Vincent FERT, CEO of HalioDx, comments: “The recognition by the WHO panel of the importance of the immune response assessment in colorectal cancer is a key landmark for Immunoscore® and HalioDx. It supports our efforts to make this outstanding technology available to improve cancer care worldwide.”

The work on Immunoscore was initiated at the French National Institute of Health and Medical Research (INSERM) (Galon et al Science 2006), and it’s international validation supported by the Society for ImmunoTherapy of Cancer (SITC) (Pagès et al. Lancet 2018).

About Immunoscore®

Immunity Assessed, Personalized Treatment

Evaluated as an essential and desirable diagnostic criteria by the WHO, immune response assessment is becoming now the necessary complement to the traditional cancer staging system and Immunoscore® is the diagnostic standard to perform this evaluation.

Today, Immunoscore® includes a unique family of immune-based assays, ranging from diagnostic tests such as Immunoscore® Colon (CE-marked In Vitro Diagnostic and CLIA compliant) and Immunoscore® family assays for clinical research. At the forefront of Multiplex Spatial Tissue Analysis, these assays combine proprietary multiplexed immunohistochemistry, advanced image analysis and computerised algorithms.

By precisely quantifying immune cell infiltration in and around the tumor, Immunoscore® has already proven its superior prognostic value than the usual tumor risk parameters, notably in localised colon cancer. Today, Immunoscore® is investigated in a broad number of clinical studies and cancer indications for establishing its performances as a prognostic factor as well as a predictive factor for response to drugs, notably chemotherapies and immunotherapies.

Immunoscore® is commercially available in more than 20 countries.

[1] Disclaimer: The World Health Organization is not endorsing the Immunoscore® commercial assay.

[2] T describes the size of the tumor and any spread of cancer into nearby tissue; N describes spread of cancer to nearby lymph nodes; and M describes metastasis (spread of cancer to other parts of the body).